- Record: found
- Abstract: not found
- Article: not found
Bortezomib-based regimens used as induction in newly diagnosed multiple myeloma (ndMM) patients eligible for stem cell transplantation (SCT) the cost-utility analysis
Read this article at
ScienceOpen
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.